Detalhe da pesquisa
1.
Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.
Oncologist
; 24(5): 648-656, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30591549
2.
Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
Oncologist
; 23(3): 328-336, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29317551
3.
The Association Between Baseline Hepatic or Renal Function and Clinical Outcomes for Patients With Non-Small Cell Lung Cancer Treated With a PD-1/PD-L1 Blocking Antibody Using Real-World and Trial Data.
Clin Pharmacol Ther
; 113(5): 1139-1149, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36790088